Glaxosmithkline has a share of around 5% of the world’s pharmaceutical market, aiming to tackle 3 of the ‘priority’ diseases identified by the World Health Organisation. The company employs around 96,500 people in over 100 countries. In 2010 they delivered 1.4 billion vaccine doses to 179 countries.
I'd take a look at Novartis ADR, they produce drugs at a cheaper cost especially for developing countries. They have a good dividend policy which has increased for the past 18years, since it first came about. Further it has the best portfolio of medicine and has a great gearing to debt levels. Lastly, Novartis has. $50bn stake in Roche Holdings, which they have been mooted to selling, which would give them massive firepower to make a big acquisition, and also they have the biggest segment in eye care. Plus its trading on a cheaper P/E basis to JNJ, GSK, PFE, MRK, RHHBY, TEVA.
judging by your name trader take your profit and keep away from aim stocks
if you sell you will be pleased to see them fall 2 quid if you hold and they fall you will be kicking yourself if they go up another 2 quid how will you feel ???
http://www.barchart.com/opinions/stocks/GSK the americans are driving this stock higher chasing yield and 4 .5 pc looks good to them and they like stock buybacks
i bought in gsk 7 years ago. seen a low of 10 quid and a high of 17 70 plus about 425 in dividends. this last 4 months have been good. lots of guys sold at 15 quid and thought they called the high i bet they regret selling now if you are happy with the profit then take it but remember you have to find another home for the money you invested
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.